#btk-inhibitors — Friday, October 23, 2026 (1 items)
| 15 | ℹ |
Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials.
(linkinghub.elsevier.com)
|
The Lancet 2026-10-23 | #multiple sclerosis #clinical-trials #immunotherapy #relapse #btk-inhibitors |